Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) Return on Assets (2019 - 2025)

BridgeBio Pharma's Return on Assets history spans 7 years, with the latest figure at 0.69% for Q4 2025.

  • For Q4 2025, Return on Assets fell 5.0% year-over-year to 0.69%; the TTM value through Dec 2025 reached 0.69%, down 5.0%, while the annual FY2025 figure was 0.79%, 5.0% down from the prior year.
  • Return on Assets for Q4 2025 was 0.69% at BridgeBio Pharma, roughly flat from 0.69% in the prior quarter.
  • Across five years, Return on Assets topped out at 0.51% in Q2 2021 and bottomed at 1.12% in Q4 2023.
  • The 5-year median for Return on Assets is 0.7% (2022), against an average of 0.75%.
  • The largest annual shift saw Return on Assets dropped -30bps in 2023 before it soared 49bps in 2024.
  • A 5-year view of Return on Assets shows it stood at 0.69% in 2021, then dropped by -25bps to 0.87% in 2022, then dropped by -29bps to 1.12% in 2023, then skyrocketed by 43bps to 0.63% in 2024, then decreased by -9bps to 0.69% in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Return on Assets are 0.69% (Q4 2025), 0.69% (Q3 2025), and 0.75% (Q2 2025).